Rocket Pharmaceuticals Inc

RCKTNASDAQ · USD
2.60USD0.00 (-3.54%)
137

Rocket Pharmaceuticals Inc (RCKT) Implied Volatility Current

RCKT implied volatility is 455%. IV Rank is 98%, placing current premiums in the top of their 52-week range.

Read more

Tracking RCKT implied volatility helps you identify when options premiums on Rocket Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Rocket Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when RCKT IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Rocket Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For RCKT, tracking metrics like RCKT IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on RCKT signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where RCKT implied volatility sits today versus where it has been. Our scanner ranks Rocket Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in RCKT IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Rocket Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.

Implied Volatility

IV Rank
98.41%IV Rank
High

IV is near its yearly peak - premiums are expensive, favoring sellers.

Implied Volatility (30d)454.86%

IV Rank98.41%

Historical Volatility (30d)71.04%

IV - HV+383.82%

As of September 25, 2026

Trade options with IV on your side

Track RCKT IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.

Start your 14-day free trial